Complete publications - Dr Phillip Stricker

Focal Therapy

Valerio, M, Stricker PD, H. U. Ahmed, L. Dickinson, L. Ponsky, Shnier R, C. Allen, and M. Emberton. 2014. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis, 17: 343 https://doi.org/10.1038/pcan.2014.33

Ting F, M. Tran, M. Böhm, Siriwardana A, van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, and Stricker PD. 2015. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer And Prostatic Diseases, 19: 46. https://doi.org/10.1038/pcan.2015.47

Ting F, van Leeuwen PJ, and Stricker PD. 2016. Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide. J Vasc Interv Radiol, 27: 568. https://doi.org/10.1016/j.jvir.2016.01.003

Scheltema M.J, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, and Stricker PD. 2017. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU Int, 120 Suppl 3: 51-58. https://doi.org/10.1111/bju.13991

Scheltema MJ, Chang JI, Bohm M, van den Bos W, A. Blazevski, Gielchinsky I, Kalsbeek AMF, van Leeuwen PJ, Nguyen TV T. M. de Reijke, Siriwardana AR, Thompson JE, J. J. de la Rosette, and Stricker PD. 2018. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol. https://doi.org/10.1007/s00345-018-2281-z

Van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, and Stricker PD. 2018. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int, 121: 716-24. https://doi.org/10.1111/bju.13983

Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV T. M. Reijke, Siriwardana AR, Bohm M, J. J. de la Rosette, and Stricker PD. 2018. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol, 24: 268-75. https://doi.org/10.5152/dir.2018.17374

Scheltema M.J, T. J. O’Brien, van den Bos W, D. M. de Bruin, R. V. Davalos, C. W. M. van den Geld, M. P. Laguna, R. E. Neal, 2nd, I. M. Varkarakis, A. Skolarikos, Stricker PD, T. M. de Reijke, C. B. Arena and J. de la Rosette (2019). umerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences. Ther Adv Urol 11: 1756287219852305. https://doi.org/10.1177/1756287219852305

Blazevski, A, Scheltema MJ, A. Amin, Thompson JE, N. Lawrentschuk and Stricker PD (2019). rreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. https://doi.org/10.1111/bju.14951

Blazevski A, Scheltema MJ, Yuen B Masand N, Nguyen TV W.Delprado, Shnier R, A. Haynes, Cusick T, Thompson J, Stricker P. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Eur Urol. Oncol(2019). https://doi.org/10.1016/j.euo.2019.04.008

Blazevski, A, Scheltema MJ, A. Amin, Thompson JE, N. Lawrentschuk and Stricker PD (2020). Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int 125(3): 369-378. https://doi.org/10.1111/bju.14951

Blazevski A, Amin A, Scheltema MJ, Balakrishnan A, Haynes AM, Barreto D, Cusick T, Thompson J, Stricker PD. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World J Urol. 2021 Apr;39(4):1107-1114. https://doi.org/10.1007/s00345-020-03275-z Epub 2020 Jun 2.

Cussenot O, Stricker PD. Irreversible electroporation for patients with localised prostate cancer: Expert opinion on this versatile therapeutic approach. EMJ Urol. 2021 Aug:9[1]:56-62. https://www.emjreviews.com/urology/article/irreversible-electroporation-for-patients-with-localised-prostate-cancer-expert-opinion-on-this-versatile-therapeutic-approach-j180121

Blazevski A, Gondoputro W, Scheltema MJ, Amin A, Geboers B, Barreto D, Haynes AM, Shnier R, Delprado W, Agrawal S, Thompson JE, Stricker PD. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes. BMC Urol. 2022 Mar 2;22(1):28. https://doi.org/10.1186/s12894-022-00978-w.

Geboers B, Gondoputro W, Thompson JE, Reesink DJ, van Riel LAMJG, Zhang D, Blazevski A, Doan P, Agrawal S, Matthews J, Haynes AM, Liu Z, Delprado W, Shnier R, de Reijke TM, Lawrentschuk N, Stijns PEF, Yaxley JW, Scheltema MJ, Stricker PD. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study. Eur Urol Focus. 2022 May 13:S2405-4569(22)00106-7. https://doi.org/10.1016/j.euf.2022.04.010. Epub ahead of print.

Van Riel LAMJG, Geboers B, Kabaktepe E, Blazevski A, Reesink DJ, Stijns P, Stricker PD, Casanova J, Dominguez-Escrig JL, de Reijke TM, Scheltema MJ, Oddens JR. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU Int. 2022 Apr 27. https://doi.org/10.1111/bju.15759. Epub ahead of print.

Ong S, Chen K, Grummet J, Yaxley J, Scheltema MJ, Stricker P, Tay KJ, Lawrentschuk N. Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? BJU Int. 2022 Sep 9. https://doi.org/10.1111/bju.15883. Epub ahead of print.

Scheltema M.J, Geboers, B, Blazevski, A, Doan, P, Katelaris, A, Agrawal, S, Barreto, D, Shnier, R, Delprado, W, Thompson, J. E, & Stricker, P. D. (2022). Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU international, 10.1111/bju.15946. Advance online publication. https://doi.org/10.1111/bju.15946

Blazevski, A, Geboers, B, Scheltema M.J, Gondoputro, W, Doan, P, Katelaris, A, Agrawal, S, Baretto, D, Matthews, J, Haynes, A. M, Delprado, W, Shnier, R, Van den Bos W, Thompson, J. E, Lawrentschuk, N, & Stricker, P. D. (2022). Salvage irreversible electroporation for radio-recurrent prostate cancer – the prospective FIRE trial. BJU international, 10.1111/bju.15947. Advance online publication. https://doi.org/10.1111/bju.15947

Geboers, B, Scheltema M.J, Blazevski, A, Katelaris, A, Doan, P, Ali, I, Agrawal, S, Barreto, D, Matthews, J, Haynes, A. M, Delprado, W, Shnier, R, Thompson, J. E, & Stricker, P. D. (2023). Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer. BJU international, 10.1111/bju.15948. Advance online publication. https://doi.org/10.1111/bju.15948

Emberton M, Reijke T;, Stricker P, Miñana, Bianco F, Dominguez Escrig J, Lantz A, Sanchez-Salas R. Revisiting Delphi to create a basis for the future of focal therapy for prostate cancer. Urology Journal URL-D-23-00730

Lantz A, Nordlund P, Falagario U, Jäderling F, Özbek O, Clements M, Discacciati A, Grönberg H, Eklund M, Stricker P, Emberton M, Aly M, Nordström T. Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. Eur Urol Open Sci. 2023 Apr 8;51:89-94. https://doi.org/10.1016/j.euros.2023.03.003 . PMID: 37091033; PMCID: PMC10114162.

Deivasigamani S, Kotamarti S, Rastinehad AR, et al. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023;84(6):547-560. https://doi.org/10.1016/j.eururo.2023.06.013. Epub ahead of print. PMID: 37419773.

Scheltema MJ, Katelaris A, Stricker PD. Salvage irreversible electroporation for radio-recurrent prostate cancer. Nat Rev Urol. 2023 Mar 1. https://doi.org/10.1038/s41585-023-00750-1 . Epub ahead of print. PMID: 36859611.

Rodríguez-Sánchez L, Emberton M, de Reijke T, Stricker P, Miñana B, Bianco F, Escrig JLD, Lantz A, Sanchez-Salas R. Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer. World J Mens Health. 2023 Oct 16. DOI: 10.5534/wjmh.230160. Epub ahead of print. PMID: 37853538.

Zhang K, Stricker P, Löhr M, Stehling M, Suberville M, Cussenot O, Lunelli L, Ng CF, Teoh J, Laguna P, de la Rosette J. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate cancer and prostatic diseases. 2024 Jan 9. https://doi.org/10.1038/s41391-023-00783-y”. Epub ahead of print. PMID: 38195916.

Geboers B, Meijer D, Counter W, et al. Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU Int. 2024;133 Suppl 4:14-22. https://doi:10.1111/bju.16207

Williams ISC, Katelaris A, Geboers B, Doan P, Delprado W, Scheltema MJ, Stricker P. Transrectal Ultrasound as Real-Time Confirmation of Adequate Needle Positioning During Irreversible Electroporation in Focal Therapy of Prostate Cancer. Videourology 37, pp. 1 – 2 https://doi.org/10.1089/vid.2023.0046

Geboers B, Scheltema MJ, Jung J … Stricker PD. Irreversible Electroporation of Intermediate risk prostate cancer mitigates immune suppression and induces systemic antitumor T cell activation Presented at USANZ Annual Scientific Meeting 2024

Active Surveillance

Thompson, J. E, A. Hayen, A. Landau, Haynes AM, A. Kalapara, J. Ischia, J. Matthews, M. Frydenberg, and Stricker PD. 2015. Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. BJU Int, 115: 884-91. https://doi.org/10.1111/bju.12858

Bayliss, D, J. Duff, Stricker P, and K. Walker. 2016. Decision-Making in Prostate Cancer: Active Surveillance Over Other Treatment Options. Urol Nurs, 36: 141-9.

Galvao, D. A, D. R. Taaffe, N. Spry, R. A. Gardiner, R. Taylor, G. P. Risbridger, M. Frydenberg, M. Hill, S. K. Chambers, Stricker P, T. Shannon, D. Hayne, E. Zopf, and R. U. Newton. 2016. Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nat Rev Urol, 13: 258-65. https://doi.org/10.1038/nrurol.2016.46

Amin, A, Scheltema MJ, Shnier R, A. Blazevski, D. Moses, Cusick T, A. Siriwardena, Yuen B P. J. v. Leeuwen, Haynes AM, J. Matthews, P. Brenner, G. O’Neill, Yuen C, Delprado W, Stricker P and Thompson J (2020) “The MRI in Active Surveillance (MRIAS); Trial: Use of Baseline mpMRI and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies. Journal of Urology 0(0):10.1097 https://doi.org/10.1097/JU.0000000000000693

Cooperberg MR, Zheng Y, Faino AV, et al. Tailoring intensity of Active surveillance for low-risk prostate cancer based on online August 27, 2020. http://DOI:10.1001/jamaoncol.2020.3187

Watson V, McCartan N, Krucien N, Abu V, Ikenwilo D, Emberton M, Ahmed HU. Evaluating the Trade-offs Men with Localized Prostate Cancer Make between the Risks and Benefits of Treatments: The COMPARE Study. The Journal of Urology. 2020 Jan 22:10-97. https://doi.org/10.1097/JU.0000000000000754

Imaging

Thompson J, N. Lawrentschuk, M. Frydenberg, L. Thompson, and Stricker P. 2013. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int, 112 Suppl 2: 6-20. https://doi.org/10.1111/bju.12381

Thompson, J. E, D. Moses, Shnier R, P. Brenner, Delprado W, L. Ponsky, M. Pulbrook, Bohm M, Haynes AM, A. Hayen, and Stricker PD. 2014. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol, 192: 67-74. https://doi.org/10.1016/j.juro.2014.01.014

Morigi, J. J, Stricker PD, van Leeuwen PJ, Tang R, B. Ho, Nguyen Q, Hruby G, Fogarty G, R. Jagavkar, A. Kneebone, A. Hickey, S. Fanti, L. Tarlinton, and Emmett L. 2015. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med, 56: 1185-90. https://doi.org/10.2967/jnumed.115.160382

van Leeuwen, P. J, Stricker P, Hruby G, A. Kneebone, Ting F, B. Thompson, Nguyen Q, B. Ho, and Emmett L. 2016. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int, 117: 732-9. https://doi.org/10.1111/bju.13397

Emmett, L, van Leeuwen PJ, R. Nandurkar, Scheltema MJ, Cusick T, Hruby G, A. Kneebone, T. Eade, Fogarty G, R. Jagavkar, Nguyen Q, B. Ho, A. M. Joshua, and Stricker P. 2017. Treatment Outcomes from (68)Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. J Nucl Med, 58: 1972-76. https://doi.org/10.2967/jnumed.117.196683

Ginsburg, S. B, A. Algohary, S. Pahwa, V. Gulani, L. Ponsky, H. J. Aronen, P. J. Bostrom, Bohm M, Haynes AM, P. Brenner, Delprado W, Thompson J, M. Pulbrock, P. Taimen, R. Villani, Stricker P, A. R. Rastinehad, I. Jambor, and A. Madabhushi. 2017. Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. J Magn Reson Imaging. 2017 Jul;46(1):184-193. https://doi.org/10.1002/jmri.25562

Thompson, J. E, van Leeuwen PJ, D. Moses, Shnier R, P. Brenner, Delprado W, M. Pulbrook, Bohm M, Haynes AM, A. Hayen, and Stricker PD. 2016. The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer. J Urol, 195: 1428-35. https://doi.org/10.1016/j.juro.2015.10.140

Ting F, van Leeuwen PJ, Thompson J, Shnier R, D. Moses, Delprado W, and Stricker PD. 2016. Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy. Prostate Cancer, 2016: 3794738. https://doi.org/10.1155/2016/3794738

Tran, M, Thompson J, M. Böhm, M. Pulbrook, D. Moses, Shnier R, P. Brenner, Delprado W, AM. Haynes, Savdie R, and Stricker P. 2016. Combination of multiparametric MRI and transperineal template‐guided mapping biopsy of the prostate to identify candidates for hemi‐ablative focal therapy. BJU International, 117: 48-54. https://doi.org/10.1111/bju.13090

Rusu, M, A. S. Purysko, S.Verma, J. Kiechle, J.Gollamudi, S. Ghose, K.Herrmann, V. Gulani, R. Paspulati, L. Ponsky, M. Böhm, A.M. Haynes, D. Moses, Shnier R, Delprado W, Thompson J, Stricker P, and A. Madabhushi. 2017. Computational imaging reveals shape differences between normal and malignant prostates on MRI. Scientific Reports, 7: 41261. DOI: doi.org/10.1038/srep41261

Scheltema MJ, Chang JI, van den Bos W, Bohm M, Delprado W, Gielchinsky I, T. M. de Reijke, J. J. de la Rosette, Siriwardana AR, Shnier R, and Stricker PD. 2017. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation. Eur Urol Focus. https://doi.org/10.1016/j.euf.2017.10.007

Siriwardana, A, Thompson J, van Leeuwen PJ, Doig S Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes AM, Coughlin G, and Stricker P. 2017. Initial multicentre experience of (68) gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int, 120: 673-81. https://doi.org/10.1111/bju.13919

Siriwardana, A, W van den Bos, Thompson J, Shnier R, and P.D. Stricker. 2017. The role of MRI in prostate cancer: A changing paradigm. MedicineToday, 18 .

Thompson J, and Stricker P. 2017. MRI improves cost and accuracy of prostate cancer biopsy. Nature Reviews Urology, 15: 6. https://doi.org/10.1038/nrurol.2017.185

Thompson, J. E, and Stricker PD. 2017. Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. Lancet, 389: 767-68. https://doi.org/10.1016/s0140-6736(17)30121-6

van Leeuwen, P. J, Emmett L, B. Ho, Delprado W, Ting F, Nguyen Q, and Stricker PD. 2017. Prospective evaluation of 68Gallium- prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int, 119: 209-15. https://doi.org/10.1111/bju.13540

van Leeuwen, P. J, A. Hayen, Thompson JE, D. Moses, Shnier R, Bohm M, M. Abuodha, Haynes AM, Ting F, J. Barentsz, M. Roobol, J. Vass, K. Rasiah, Delprado W, and Stricker PD. 2017. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int, 120: 774-81. DOI: doi.org/10.1111/bju.13814

Algohary, A, S. Viswanath, R. Shiradkar, S. Ghose, S. Pahwa, D. Moses, I. Jambor, Shnier R, Bohm M, Haynes AM, P. Brenner, Delprado W, Thompson J, M. Pulbrock, A. S. Purysko, S. Verma, L. Ponsky, Stricker P, and A. Madabhushi. 2018. Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings. J Magn Reson Imaging. https://doi.org/10.1002/jmri.25983

Emmett, L, R. Nandurkar, P. Van Leeuwen, H. Woo, R. Kooner, D. Ende, G. O’Neill, Yuen C, B. Ho, Nguyen Q, A. Hickey, and Stricker P. 2018. Staging with Ga-68 HBED-CC-Glu-NH-CO-NH-Lys (Ahx) PSMA-11 PET CT (PSMA) prior to radical prostatectomy has high predictive value in assessing biochemical response to surgery. European Urology Supplements, 17: e1903. https://doi.org/10.1016/S1569-9056(18)32310-8

Roach, P. J, R. Francis, Emmett L, E. Hsiao, A. Kneebone, Hruby G, T. Eade, Q. A. Nguyen, B. D. Thompson, Cusick T, M. McCarthy, C. Tang, B. Ho, Stricker PD, and A. M. Scott. 2018. The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med, 59: 82-88. https://doi.org/10.2967/jnumed.117.197160

Gielchinsky, I, Scheltema MJ, Cusick T, Chang J, Shnier R, D. Moses, Delprado W, Nguyen Q, Yuen C, Haynes AM, and Stricker PD. 2018. Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50. Res Rep Urol, 10: https://doi.org/10.2147/RRU.S169017

Penzias, G, A. Singanamalli, R. Elliott, J. Gollamudi, Shih N Feldman M, Stricker PD, Delprado W, S. Tiwari, Bohm M, Haynes AM, L. Ponsky, P. Fu, P. Tiwari, S. Viswanath, and A. Madabhushi. 2018. Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings. PLoS One, 13: e0200730. https://doi.org/10.1371/journal.pone.0200730

Thompson, J. E, and Stricker PD. 2018. MRI improves active surveillance of prostate cancer however biopsy is still crucial. BJU Int, 122: E1-E2. https://doi.org/10.1111/bju.14424

Emmett, L, M. Crumbaker, B. Ho, K. Willowson, P. Eu, L. Ratnayake, R. Epstein, A. Blanksby, L. Horvath, A. Guminski, K. Mahon, C. Gedye, C. Yin, Stricker P and A. M. Joshua (2019). esults of a Prospective Phase 2 Pilot Trial of (177)Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. Clin Genitourin Cancer 17(1): 15-22. https://doi.org/10.1016/j.clgc.2018.09.014

Van Leeuwen, P. J, Emmett L, M. L. Donswijk, Stricker PD, F. J. Pos, E. M. K. Wit and H. G. van der Poel (2019). ‘Early outcomes after [68Ga]PSMA-PET/CT guided salvage therapy in men with biochemical recurrence after radical prostatectomy | [Vroege oncologische uitkomsten van [68Ga]PSMA-PET/CT-gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie] Tijdschrift voor Urologie 9(1): 2-8. https://doi.org/10.1007/s13629-018-00215-w

Nandurkar, R, P. van Leeuwen, Stricker P, H. Woo, R. Kooner, Yuen C, G. O’Neill, D. Ende, Cusick T, B. Ho, A. Hickey and Emmett L (2019). 68)Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. Br J Radiol 92(1095): 20180667. https://doi.org/10.1259/bjr.20180667

Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Q. A. Nguyen, B. Ho, Delprado W, J. Lee, Thompson JE, Cusick T, A. S. Spriensma, Siriwardana AR, Yuen C, R. Kooner, Hruby G, G. O’Neill and Emmett L (2019). iagnostic accuracy of (68) Ga- prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole- mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. BJU Int. https://doi.org/10.1111/bju.14794

Emmett, L, Tang R, R. H. Nandurkar, Hruby G, P. J. Roach, J. A. Watts, Cusick T, A. Kneebone, B. Ho, L. Chan, P. van Leeuwen, M. Scheltema, A. Nguyen, C. Yin, A. Scott, C. Tang, M. McCarthy, K. Fullard, M. Roberts, R. Francis and Stricker P (2019). -year freedom from progression following (68)GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trial. J Nucl Med. https://doi.org/10.2967/jnumed.119.235028

Algohary, A, R. Shiradkar, S. Pahwa, A. Purysko, S. Verma, D. Moses, Shnier R, Haynes AM, Delprado W, Thompson J, S. Tirumani, A. Mahran, A. R. Rastinehad, L. Ponsky, Stricker PD and A. Madabhushi (2020). ombination of Peri-Tumoral and Intra- Tumoral Radiomic Features on Bi-Parametric MRI Accurately Stratifies Prostate Cancer Risk: A Multi-Site Study. Cancers (Basel) 12(8). https://doi.org.au/10.3390/cancers12082200

Louise Emmett, James Buteau, Nathan Papa, Daniel Moon, James Thompson, Matthew Roberts, Kris Rasiah, David Pattison, John Yaxley, Paul Thomas, Anthony Hutton, Shikha Agrawal, Amer Amin, Alexandar Blazevski, Venu Chalasani, Bao Ho, Andrew Nguyen, Victor Liu, Jonathan Lee, Gemma Sheehan-Dare, Raji Kooner, Geoff Coughlin, Lyn Chan, Thomas Cusick, Benjamin Namdarian, Jada Kapoor, Omar Alghazo, Henry Woo, Nathan Lawrentschuk, Declan Murphy, Michael Hofman, Stricker P. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography To Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021.ISSN 0302-2838. https://doi.org/10.1016/j.eururo.2021.08.002

Louise M Emmett, Nathan Papa, James Buteau, Bao Ho, Victor Liu, Matthew Roberts, James Thompson, Daniel Moon, Gemma Sheehan-Dare, Omar Alghazo, Shikha Agrawal, Declan G. Murphy, Stricker P, Thomas A. Hope and Michael Hofman. The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. Journal of Nuclear Medicine March 2022, jnumed.121.263448; https://doi.org/10.2967/jnumed.121.263448

Roberts MJ, Chatfield MD, Hruby G, Nandurkar R, Roach P, Watts JA, Cusick T, Kneebone A, Eade T, Ho B, Nguyen A, Tang C, McCarthy M, Francis R, Stricker P, Emmett L. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups. BJU Int. 2022 Nov;130 Suppl 3(Suppl 3):32-39. DOI: 10.1111/bju.15762. Epub 2022 Jul 12. PMID: 35488182; PMCID: PMC9796546. https://doi.org/10.1111/bju .15762

Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, Hofman M, Buteau J, Murphy DG, Emmett L, Moon D. High PSMA PET SUVmax in PI‐RADS 4 or 5 men confers a high probability of significant prostate cancer. BJU International. 2022 Apr 1. https://doi.org/10.1111/bju .15736

Doan P, Counter W, Papa N, Sheehan-Dare G, Ho B, Lee J, Liu V, Thompson JE, Agrawal S, Roberts MJ, Buteau J, Hofman MS, Moon D, Lawrentschuk N, Murphy D, Stricker PD, Emmett L. Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer. BJU Int. 2022 Nov 13. DOI: 10.1111/bju.15929. Epub ahead of print. PMID: 36371669. https://pubmed.ncbi.nlm.nih.gov/36371669/

Vis AN, Meijer D, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, Samaratunga H, Emmett L, van de Ven PM, Heymans MW, Nieuwenhuijzen JA, van der Poel HG, Donswijk ML, Boellaard TN, Schoots IG, Stricker P, Haynes AM, Oprea-Lager DE, Coughlin GD, van Leeuwen PJ. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 Apr 10:S2588-9311(23)00075-5. DOI: 10.1016/j.euo.2023.03.010. Epub ahead of print. PMID: 37045707.
Kelly B, Ptasznik G, Roberts MJ, Doan P, Stricker P, Thompson J, Buteau J, Chen K, Alghazo O, O’Brien JS, Hofman MS, Frydenberg M, Lawrentschuk N, Lundon D, Murphy DG, Emmett L and Moon D. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy, European Urology Open Science. 2023. https://doi.org/10.1016/j.euros.2023.05.002

Samaneh Azargoshasb, Hilda A. de Barros, Daphne D.D. Rietbergen, Paolo Dell’Oglio, Van Leeuwen PJ, Wagner C, Stricker P, Sergi Vidal-Sicart, Alberto Briganti, Tobias Maurer, Henk G. van der Poel, Matthias N. van Oosterom, Fijs W. B. van Leeuwen. Artificial Intelligence-Supported Video Analysis as a Means to Assess the Impact of DROP-IN Image Guidance on Robotic Surgeons: Radioguided Sentinel Lymph Node versus PSMA-Targeted Prostate Cancer Surgery. Advanced Intelligent Systems journal. 2023. https://doi.org/10.1002/aisy.202300192

Li L, Shiradkar R, Tirumani SH, Bittencourt LK, Fu P, Mahran A, Buzzy C, Stricker PD, Rastinehad AR, Magi-Galluzzi C, Ponsky L, Klein E, Purysko AS, Madabhushi A. Novel radiomic analysis on bi-parametric MRI for characterizing differences between MR non-visible and visible clinically significant prostate cancer. Eur J Radiol Open. 2023 Jun 13;10:100496. https://doi.org/10.1016/j.ejro.2023.100496 . PMID: 37396490; PMCID: PMC10311200.

Radical Prostatectomy/Robotic Surgery

Ricciardelli, C, D. I. Quinn, W. A. Raymond, K. McCaul, P. D. Sutherland, Stricker PD, J. J. Grygiel, Sutherland RL, V. R. Marshall, W. D. Tilley, and D. J. Horsfall. 1999. ‘Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res, 59: 2324-8.

Quinn, D. I, S. M. Henshall, D. R. Head, Golovsky D, Wilson JD, Brenner PC, J. Turner J, Delprado WJ, Finlayson F, Stricker PD, J. J. Grygiel, and Sutherland RL. 2000. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res, 60: 1585-94.

Quinn, D. I, S.M. Henshall, A.M. Haynes, Brenner PC, Kooner R, D. Golovsky, J. Mathews, G. F. O’Neill, J. Turner J, Delprado WJF, Finlayson F, Sutherland RL, J. J. Grygiel, and Stricker PD. 2001. Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models. Journal of Clinical Oncology, 19: 3692-705. https://doi.org/10.1200/jco.2001.19.16.3692

Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, D. I. Quinn, S. M. Henshall, J. J. Grygiel, Sutherland RL, Stricker PD, J. de Kernion, T. Cangiano, F. H. Schroder, M. F. Wildhagen, Scardino PT, and M. W. Kattan. 2002. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol, 20: 951-6. https://doi.org/10.1200/jco.2002.20.4.951

Graefen M, Karakiewicz PI, Cagiannos I, D. I. Quinn, S. M. Henshall, J. J. Grygiel, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, H. Huland, P. G. Hammerer, A. Haese, A. Erbersdobler, Eastham JA, J. de Kernion, T. Cangiano, F. H. Schroder, M. F. Wildhagen, T. H. van der Kwast, Scardino PT, and M. W. Kattan. 2002. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol, 20: 3206-12. https://doi.org/10.1200/jco.2002.12.019

Quinn, D. I, S. M. Henshall, Brenner PC,, R. Kooner, D. Golovsky, G. F. O’Neill, J. Turner J, Delprado W, J. J. Grygiel, Sutherland RL, and Stricker PD. 2003. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer, 97: 1884-93. https://doi.org/10.1002/cncr.11263

Stricker, P, J Matthews, and Haynes AM. 2004. Radical Prostatectomy: A personal series of 700 cases over 14 years: Evolution in technique. ANZ Journal of Surgery, 74: A1-A8.

Cagiannos, I, P. Karakiewicz, M. Graefen, Eastham JA, M. Ohori, F. Rabbani, V. Reuter, T. Wheeler, Kupelian P, Klein E, H. Huland, P. G. Hammerer, A. Erbersdobler, F. Schroeder, M. Wildhagen, D. I. Quinn, S. M. Henshall, J. J. Grygiel, Sutherland RL, Stricker PD, C. G. Morash, Scardino PT, and M. W. Kattan. 2004. Is year of radical prostatectomy a predictor of outcome in prostate cancer?. J Urol, 171: 692-6. https://doi.org/10.1097/01.ju.0000107260.98031.0e

Montorsi, F, Stricker P, E. Jaudinot, C. Wohlhuter, P. Puppo, and P. Teillac. 2004. Stratification by outcomes affecting response to Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy. European Urology Supplements, 3: 32. https://doi.org/10.1016/S1569-9056(04)90121-2

Teillac, P, Stricker P, E. Jaudinot, C. Wohlhuter, and F. Montorsi. 2004. Efficacy and safety of Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy. European Urology Supplements, 3: 33. https://doi.org/10.1016/S1569-9056(04)90124-8

Henshall, S. M, L. G. Horvath, D. I. Quinn, S. A. Eggleton, J. J. Grygiel, Stricker PD, A. V. Biankin, J. G. Kench, and Sutherland RL. 2006. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst, 98: 1420-4. https://doi.org/10.1093/jnci/djj378

Macek P, Stricker P, M. Stevens, R. Jagavkar, V. Chalasani, A.M. Haynes, J Mathews, P. Brenner, D. Golovsky, R Kooner, and F. O’Neill G. 2006. Outcomes of radical prostatectomies and HDR brachytherapy in patients with intermediate and high risk prostate cancer. BJU International, 97: 3-3. https://doi.org/10.1111/j.1464-410X.2006.06085_12.x

Padma-Nathan, H, A. R. McCullough, L. A. Levine, L. I. Lipshultz, R. Siegel, F. Montorsi, F. Giuliano, and G. Brock. 2008. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res, 20: 479-86. https://doi.org/10.1038/ijir.2008.33

Stricker, P. 2008. Ethical Introduction to Robotic Radical Prostatectomy Surgery for an Experienced Open Surgeon. Journal of Robotic Surgery, 2: 105-33.

Stricker, P. 2008. Approaches to Nerve Sparing Retrograde Athermal Technique. Journal of Robotic Surgery, 2: 105-33.

Chen, P, R. Thanigasalam, Stricker P, J Mathews, R. DeBenito, Haynes AM, S. M. Henshall, and K. K. Rasiah. 2009. The Clinico- Pathological Outcome of Men Undergoing Prostatectomy with PSA < 4. BJUI International, 103: 1-48. https://doi.org/10.1111/j.1464-410X.2009.09021.x

Chen, P, R. Thanigasalm, S. M. Henshall, Haynes AM, J Mathews, and Stricker P. 2009. Prospective Comparative Analysis of Clinico-Pathological Outcomes Between Robotic Assisted and Open Radical Prostatectomy. BJUI International, 103: 1-48. https://doi.org/10.1111/j.1464-410X.2009.09021.x

Doumerc, N, Yuen C, Savdie R, M. B. Rahman, R. Pe Benito, and Stricker P. 2010. Robot-assisted laparoscopic prostatectomy: analysis of an experienced open surgeon’s learning curve after 300 procedures. J Robot Surg, 3: 229-34. https://doi.org/10.1007/s11701-010-0171-5

Doumerc, N, Yuen C, Savdie R, M. B. Rahman, K. K. Rasiah, R. Pe Benito, Delprado W, J. Matthews, Haynes AM, and Stricker PD. 2010. Should experienced open prostatic surgeons convert to robotic surgery? The real learning curve for one surgeon over 3 years. BJU Int, 106: 378-84. https://doi.org/10.1111/j.1464-410X.2009.09158.x

Moore, B, R. DeBenito, Haynes AM, and Stricker P. 2010. The Impact of Nerve Sparing Surgical Margins Status and Oncological Outcome in Radical Prostatectomy. BJU International Authours Journal Compliation, 105: 1-38. https://doi.org/10.1111/j.1464-410X.2010.09122.x

Talantov, D, T. A. Jatkoe, Bohm M, Y. Zhang, A. M. Ferguson, Stricker PD, M. W. Kattan, Sutherland RL, J. G. Kench, Y. Wang, and S. M. Henshall. 2010. Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. J Urol, 184: 1521-8. https://doi.org/10.1016/j.juro.2010.05.084

Thanigasalam, R, K. K. Rasiah, Stricker PD, Haynes AM, S. I. Sutherland, Sutherland RL, S. M. Henshall, and L. G. Horvath. 2010. Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU Int, 105: 642-7. https://doi.org/10.1111/j.1464-410X.2009.08842.x

Hossack, T, M. I. Patel, Huo A, P. Brenner, Yuen C, D. Spernat, J. Mathews, Haynes AM, R. Sutherland, W. del Prado, and Stricker P. 2012. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. J Urol, 188: 781-5. https://doi.org/10.1016/j.juro.2012.05.006

Huo, A. S, T. Hossack, J. L. Symons, R. PeBenito, W. J. Delprado, P. Brenner, and Stricker PD. 2012. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. J Urol, 187: 2044-9. https://doi.org/10.1016/j.juro.2012.01.066

Moore, B. M, Savdie R, R. A. PeBenito, Haynes AM, J. Matthews, Delprado W, K. K. Rasiah, and Stricker PD. 2012. The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy. BJU Int, 109: 533-8. https://doi.org/10.1111/j.1464-410X.2011.10361.x

Savdie, R, L. G. Horvath, R. P. Benito, K. K. Rasiah, Haynes AM, M. Chatfield, Stricker PD, J. Turner J, Delprado W, S. M. Henshall, Sutherland RL, and J. G. Kench. 2012. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int, 109: 1794-800. https://doi.org/10.1111/j.1464-410X.2011.10572.x

Savdie, R, J. Symons, D. Spernat, Yuen C, R. A. Pe Benito, Haynes AM, J. Matthews, K. K. Rasiah, R. S. Jagavkar, C. Yu, Fogarty G, M. W. Kattan, P. Brenner, Sutherland RL, and Stricker PD. 2012. High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse. BJU Int, 110 Suppl 4: 71-6. https://doi.org/10.1111/j.1464-410X.2012.11480.x

Beattie, K, J. Symons, S. Chopra, Yuen C, Savdie R, R. Thanigasalam, Haynes AM, J. Matthews, Brenner PC,, K. Rasiah, Sutherland RL, and Stricker PD. 2013. A novel method of bladder neck imbrication to improve early urinary continence following robotic-assisted radical prostatectomy. Journal of Robotic Surgery, 7: 193-99. https://doi.org/10.1007/s11701-012-0371-2

Sooriakumaran, P, A. Srivastava, S. F. Shariat, Stricker PD, T. Ahlering, C. G. Eden, P. N. Wiklund, R. Sanchez-Salas, A. Mottrie, D. Lee, D. E. Neal, R. Ghavamian, P. Nyirady, A. Nilsson, S. Carlsson, E. Xylinas, W. Loidl, C. Seitz, P. Schramek, C. Roehrborn, X. Cathelineau, D. Skarecky, G. Shaw, A. Warren, W. J. Delprado, M. Haynes, E. Steyerberg, M. J. Roobol, and A. K. Tewari. 2014. A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot- assisted radical prostatectomy patients. Eur Urol, 66: 450-6. https://doi.org/10.1016/j.eururo.2013.11.018

Thompson, J. E, S. Egger, Bohm M, Haynes AM, J. Matthews, K. Rasiah, and Stricker PD. 2014. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. Eur Urol, 65: 521-31. https://doi.org/10.1016/j.eururo.2013.10.030

Grogan, J, R. Gupta, K. L. Mahon, Stricker PD, Haynes AM, Delprado W, Turner J, L. G. Horvath, and J. G. Kench. 2017. Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up. BJU Int, 120: 651-58. https://doi.org/10.1111/bju.13857

Thompson, J. E, S. Egger, Bohm M, Siriwardana AR, Haynes AM, J. Matthews, Scheltema MJ, and Stricker PD. 2018. Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases. Eur Urol, 73: 664-71. https://doi.org/10.1016/j.eururo.2017.11.035

Zhang, A. Y, K. Chiam, Y. Haupt, S. B. Fox, S. Birch, W.Tilley, L. Butler, K. E. Knudsen, C. Cornstock, K. Rasiah, J. Grogan, K.L. Mahon, T. Bianco-Miotto, Bohm M, S. M. Henshall, Delprado W, Stricker P, L. Horvath, and J. Kench. 2018. An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Journal of Clinical Oncology, 36: 54-54. https://doi.org/10.1200/JCO.2018.36.6_suppl.54

Zhang, A. Y, K. Chiam, Y. Haupt, S. Fox, S. Birch, W. Tilley, L. M. Butler, K. Knudsen, C. Comstock, K. Rasiah, J. Grogan, K. L. Mahon, T. Bianco-Miotto, C. Ricciardelli, Bohm M, S. Henshall, Delprado W, Stricker P, L. G. Horvath, and J. G. Kench. 2018. An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy. Int J Cancer. https://doi.org/10.1002/ijc.31906

van Leeuwen, P. J, M. Donswijk, R. Nandurkar, Stricker P, B. Ho, S. Heijmink, E. M. K. Wit, C. Tillier, E. van Muilenkom, Nguyen Q, H. G. van der Poel and Emmett L (2018). 8Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer. BJU Int. https://doi.org/10.1111/bju.14506

Luiting, H. B, van Leeuwen PJ, M. B. Busstra, T. Brabander, H. G. van der Poel, M. L. Donswijk, A. N. Vis, Emmett L, Stricker PD and M. J. Roobol (2020). se of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int 125(2): 206-214. https://doi.org/10.1111/bju.14944

Gondoputro W, Blazevski A, Amin A, Scheltema M, Agrawal S, Cusick T, Van Leeuwen P, Van Leeuwen F, Emmett L, Thompson J, Stricker P. Interim results from the DETECT Trial: A prospective clinical trial evaluating 99MTC-Labelled PSMA Radioguided surgery to aid the intraoperative detection of lymph node metastases during Robot-Assisted Radical Prostatectomy and extended pelvic lymph node dissection for prostate cancer. (Abstract) The Journal of Urology. 2021Sep;206(Supplement3):e887 https://doi.org/10.1097/JU.0000000000002076.05

Gondoputro W, Thompson J, Evans M, Bolton D, Frydenberg M, Murphy DG, Haynes AM, Agrawal S, Stricker P, Papa N. How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. The Journal of urology. 2022 Jan 3:10-97 https://doi.org/10.1097/JU.0000000000002391

Vis AN, van den Bergh RC, van der Poel HG, Mottrie A, Stricker PD, Graefen M, Patel V, Rocco B, Lissenberg‐Witte B, van Leeuwen PJ. Selection of patients for nerve sparing surgery in robot‐assisted radical prostatectomy. BJUI Compass. 2021. https://doi.org/10.1002/bco2.115

Gondoputro W, Scheltema MJ, Blazevski A, Doan P, Thompson JE, Amin A, Geboers B, Agrawal S, Siriwardana AR, Van Leeuwen PJ, van Oosterom MN, Leeuwen F, Emmett L, Stricker P. Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer. Journal of Nuclear Medicine. 2022 Mar 1. jnumed.121.263743; https://doi.org/10.2967/jnumed.121.263743

de Barros HA, Remmers S, Luiting HB, van Leenders GJLH, Roobol MJ, Bekers EM, Amin A, Haynes AM, Delprado W, Stricker PD, van der Poel HG, van der Kwast TH, van Leeuwen PJ. Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. Urology. 2022 Oct;168:156-164. DOI: 10.1016/j.urology.2022.04.043. Epub 2022 Jul 5. PMID: 35803346. https://doi.org/10.1016/j.urology.2022.04.043

Best O, Canagasingham A, Liu Z, Doan P, Haynes AM, Delprado W, Maclean F, Yuen C, Stricker P, Thompson J. Index grade group is superior to composite grade group for prediction of biochemical recurrence following radical prostatectomy. Pathology. 2023 Jan 11:S0031-3025(23)00003-X. https://doi.org/10.1016/j.pathol.2022.10.012. Epub ahead of print. PMID: 36725447

Doan P, Katelaris A, Scheltema MJ, Hayen A, Amin A, Siriwardana A, Tran M, Geboers B, Gondoputro W, Haynes AM, Matthews J, Delprado W, Stricker PD, Thompson J. The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer. BMC Urol. 2023 Apr 28;23(1):68. https://doi.org/10.1016/j.pathol.2022.10.012 8-3. PMID: 37118731; PMCID: PMC10148506.

Hassan, S. P, de Leon, J, Batumalai, V, Moutrie, Z, Hogan, L, Ge, Y, Stricker, P, & Jameson, M. G. (2024). Magnetic resonance guided adaptive post prostatectomy radiotherapy: Accumulated dose comparison of different workflows. Journal of applied clinical medical physics, e14253. Advance online publication. https://doi.org/10.1002/acm2.14253

Radio Therapy

MJ, Stevens, Stricker PD, Saalfeld J, Brenner PC, Kooner R, O’Neill GFA, Duval PJ, Jagavkar RS, Cross P, and Martland J. 2003. Treatment of localized prostate cancer using a combination of high dose rate Iridium‐192 brachytherapy and external beam irradiation: Initial Australian experience. Australasian Radiology, 47: 152-60. https://doi.org/10.1046/j.0004-8461.2003.01143.x

Stevens, M, P.D. Stricker, J. Saalfeld, P. Brenner, and R Kooner. 2006. Treatment of localised prostate cancer using a combination of high dose‐rate Ir‐192 brachytherapy (HDRB) and external beam radiation therapy (EBRT): a 7 year experience. BJU International, 97: 3-4. https://doi.org/10.1111/j.1464-410X.2006.06085_13.x

Genomics

Henshall, S. M, D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, Brenner PC,, Delprado W, Stricker PD, J. J. Grygiel, and Sutherland RL. 2001. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res, 61: 423-7.

Henshall, S. M, D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, Brenner PC,, Delprado W, Stricker PD, J. J. Grygiel, and Sutherland RL. 2001. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res, 7: 544-50.

Horvath, L. G, S. M. Henshall, C. S. Lee, D. R. Head, D. I. Quinn, S. Makela, Delprado W, D. Golovsky, Brenner PC,, G. O’Neill, R. Kooner, Stricker PD, J. J. Grygiel, J. A. Gustafsson, and Sutherland RL. 2001. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res, 61: 5331-5.

Henshall, S. M, D. E. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner-Garden, Stricker PD, H. I. Scher, J. J. Grygiel, D. B. Agus, D. H. Mack, and Sutherland RL. 2003. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res, 63: 4196-203.

Henshall, S. M, D. E. Afar, K. K. Rasiah, L. G. Horvath, K. Gish, I. Caras, V. Ramakrishnan, M. Wong, U. Jeffry, J. G. Kench, D. I. Quinn, J. Turner J, Delprado W, C. S. Lee, D. Golovsky, Brenner PC,, G. F. O’Neill, R. Kooner, Stricker PD, J. J. Grygiel, D. H. Mack, and Sutherland RL. 2003. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene, 22: 6005-12. https://doi.org/10.1038/sj.onc.1206797

Afar, D. E, V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, C. O’Hara, D. Powers, R. B. DuBridge, I. Caras, R. Winter, T. Anderson, N. Solvason, Stricker PD, C. Cordon-Cardo, H. I. Scher, J. J. Grygiel, Sutherland RL, R. Murray, V. Ramakrishnan, and D. A. Law. 2004. Preclinical validation of anti-TMEFF2-auristatin E- conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther, 3: 921-32.

Horvath, L. G, S. M. Henshall, J. G. Kench, D. N. Saunders, C. S. Lee, D. Golovsky, Brenner PC,, G. F. O’Neill, R. Kooner, Stricker PD, J. J. Grygiel, and Sutherland RL. 2004. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin Cancer Res, 10: 615-25.

Horvath, L. G, S. M. Henshall, J. G. Kench, J. Turner J, D. Golovsky, Brenner PC,, G. F. O’Neill, R. Kooner, Stricker PD, J. J. Grygiel, and Sutherland RL. 2004. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate, 59: 234-42. https://doi.org/10.1002/pros.10361

Bauskin, A. R, D. A. Brown, S. Junankar, K. K. Rasiah, S. Eggleton, M. Hunter, T. Liu, D. Smith, T. Kuffner, G. J. Pankhurst, H. Johnen, P. J. Russell, W. Barret, Stricker PD, J. J. Grygiel, J. G. Kench, S. M. Henshall, Sutherland RL, and S. N. Breit. 2005. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res, 65: 23 https://doi.org/10.1158/0008-5472.can-04-3827

Horvath, L. G, S. M. Henshall, C. S. Lee, J. G. Kench, D. Golovsky, Brenner PC,, G. F. O’Neill, R. Kooner, Stricker PD, J. J. Grygiel, and Sutherland RL. 2005. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer, 113: 415-22. https://doi.org/10.1002/ijc.20599

Rasiah, K. K, J. G. Kench, M. Gardiner-Garden, A. V. Biankin, D. Golovsky, Brenner PC,, R. Kooner, F. O’Neill G, J. Turner J, Delprado W, C. S. Lee, D. A. Brown, S. N. Breit, J. J. Grygiel, L. G. Horvath, Stricker PD, Sutherland RL, and S. M. Henshall. 2006. ”Aberrant neuropeptide Y and macrophage inhibitory cytokine expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev, 15: 711-6. https://doi.org/10.1158/1055-9965.epi-05-0752

Ho, L. L, J. G. Kench, D. J. Handelsman, G. L. Scheffer, Stricker PD, J. G. Grygiel, Sutherland RL, S. M. Henshall, J. D. Allen, and L. G. Horvath. 2008. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate, 68: 1421-9. https://doi.org/10.1002/pros.20809

Sakko, A. J, M. S. Butler, S. Byers, B. J. Reinboth, J. Stahl, J. G. Kench, L. G. Horvath, Sutherland RL, Stricker PD, S. M. Henshall, V. R. Marshall, W. D. Tilley, D. J. Horsfall, and C. Ricciardelli. 2008. Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol Biomarkers Prev, 17: 2488-97. https://doi.org/10.1158/1055-9965.epi-08-0204

Rasiah, K. K, M. Gardiner-Garden, E. J. Padilla, G. Moller, J. G. Kench, M. C. Alles, S. A. Eggleton, Stricker PD, J. Adamski, Sutherland RL, S. M. Henshall, and V. M. Hayes. 2009. HSD17B overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol, 301: 89-96. https://doi.org/10.1016/j.mce.2008.11.021

Bianco-Miotto, T, K. Chiam, G. Buchanan, S. Jindal, T. K. Day, M. Thomas, M. A. Pickering, M. A. O’Loughlin, N. K. Ryan, W. A. Raymond, L. G. Horvath, J. G. Kench, Stricker PD, V. R. Marshall, Sutherland RL, S. M. Henshall, W. L. Gerald, H. I. Scher, G. P. Risbridger, J. A. Clements, L. M. Butler, W. D. Tilley, D. J. Horsfall, and C. Ricciardelli. 2010. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev, 19:2611-22. https://doi.org/10.1158/1055-9965.epi-10-0555

Yip, P. Y, J. G. Kench, K. K. Rasiah, R. P. Benito, C. S. Lee, Stricker PD, S. M. Henshall, Sutherland RL, and L. G. Horvath. 2011. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate, 71: 1638-45. https://doi.org/10.1002/pros.21381

Selth, L. A, S. L. Townley, A. G. Bert, Stricker PD, P. D. Sutherland, L. G. Horvath, G. J. Goodall, L. M. Butler, and W. D. Tilley. 2013. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer, 109: 641-50. https://doi.org/10.1038/bjc.2013.369

Birch, S. E, J. G. Kench, E. Takano, P. Chan, A. L. Chan, K. Chiam, A. S. Veillard, Stricker P, S. Haupt, Y. Haupt, L. Horvath, and S. B. Fox. 2014. Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. Ann Oncol, 25: 2392-7. https://doi.org/10.1093/annonc/mdu454

Kalsbeek, A. M, E. F. Chan, J. Grogan, D. C. Petersen, W. Jaratlerdsiri, R. Gupta, R. J. Lyons, Haynes AM, L. G. Horvath, J. G. Kench, Stricker PD, and V. M. Hayes. 2016. Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. Aging (Albany NY), 8: 2702-12. https://doi.org/10.18632/aging.101044

Zhang, A. Y, J. S. Grogan, K. L. Mahon, K. Rasiah, P. Sved, D. R. Eisinger, J. Boulas, A. Vasilaris, S. M. Henshall, Stricker PD, J. G. Kench, and L. G. Horvath. 2017. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. Ann Oncol, 28: 1903-09. https://doi.org/10.1093/annonc/mdx247

Kalsbeek, A. M. F, E. K. F. Chan, J. Grogan, D. C. Petersen, W. Jaratlerdsiri, R. Gupta, R. J. Lyons, Haynes AM, L. G. Horvath, J. G. Kench, Stricker PD, and V. M. Hayes. 2018. Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. Prostate, 78: 25-31. https://doi.org/10.1002/pros.23440

Lin, H. M, B. Y. Lee, L. Castillo, C. Spielman, J. Grogan, N. K. Yeung, J. G. Kench, Stricker PD, Haynes AM, M. M. Centenera, L. M. Butler, S. M. Shreeve, L. G. Horvath, and R. J. Daly. 2018. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate, 78: 308-17. https://doi.org/10.1002/pros.23476

Mahon, K. L, P.Stricker, J. Kench, J. Grogan, Delprado W, Turner J, L. Horvath, and D. I. Quinn. 2018. P53 as a predictor of clinical outcome in localized prostate cancer. Journal of Clinical Oncology, 36: 57-57. https://doi.org/10.1200/JCO.2018.36.6_suppl.57

Nair, S.S, PL. Luu, W. Qu, M. Maddugoda, L. Huschtscha, R. Reddel, G. Chenevix-Trench, M. Toso, J. G. Kench, L.G. Horvath, V. M. Hayes, Stricker P, T.P. Hughes, D.L. White, J.E. J. Rasko, J.J-L Wong, and S.J. Clark. 2018. Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. Epigenetics & Chromatin, 11: 24. https://doi.org/10.1186/s13072-018-0194-0

Pidsley, R, M. G. Lawrence, E. Zotenko, B. Niranjan, A. Statham, J. Song, R. M. Chabanon, W. Qu, H. Wang, M. Richards, S. S. Nair, N. J. Armstrong, H. T. Nim, M. Papargiris, P. Balanathan, H. French, T. Peters, S. Norden, A. Ryan, J. Pedersen, J. Kench, R. J. Daly, L. G. Horvath, Stricker P, M. Frydenberg, R. A. Taylor, C. Stirzaker, G. P. Risbridger, and S. J. Clark. 2018. Enduring epigenetic landmarks define the cancer microenvironment. Genome Research, 28: 625-38. https://doi.org/10.1101/gr.229070.117

Jaratlerdsiri, W, E. K. F. Chan, T. Gong, D. C. Petersen, Kalsbeek AMF, P. A. Venter, Stricker PD, M. R. Bornman, and V. M. Hayes. 2018. Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naive, High-Risk Prostate Cancer. Cancer Res. https://doi.org/10.1158/0008-5472.can-18-0254

Bruce, HM, P.D. Stricker, R. Gupta, R.R. Savdie, AM. Haynes, KL. Mahon, HM Lin, JG. Kench, and LG. Horvath. 2016. Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer. The Prostate, 76: 1491-500. https://doi.org/10.1002/pros.23233

Bancroft, E. K, S. Saya, E. C. Page, K. Myhill, S. Thomas, J. Pope, A. Chamberlain, R. Hart, W. Glover, J. Cook, D. J. Rosario, B. T. Helfand, C. Hutten Selkirk, R. Davidson, M. Longmuir, D. M. Eccles, N. Gadea, C. Brewer, J. Barwell, M. Salinas, L. Greenhalgh, M. Tischkowitz, A. Henderson, D. G. Evans, S. S. Buys, R. A. Eeles, IMPACT Collaborators* and N. K. Aaronson (2019). “Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. BJU Int 123(2): 284-292. https://doi.org/10.1111/bju.14412 *Stricker, P. D. is an author under the IMPACT Collaborators

Feng, Y, W. Jaratlerdsiri, S. M. Patrick, R. J. Lyons, Haynes AM, C. C. Collins, Stricker PD, M. S. R. Bornman and V. M. Hayes (2019). etagenomic analysis reveals a rich bacterial content in high- risk prostate tumors from African men. Prostate 79(15): 1731-1738. https://doi.org/10.1002/pros.23897

Quinn, D. I, Stricker PD, J. G. Kench, J. Grogan, Haynes AM, S. M. Henshall, J. J. Grygiel, Delprado W, J. Turner J, L. G. Horvath and K. L. Mahon (2019). “p53 nuclear accumulation as an early indicator of lethal prostate cancer. Br J Cancer 121(7): 578-583. https://doi.org/10.1038/s41416-019-0549-8

Crumbaker, M, E. K. F. Chan, T. Gong, N. Corcoran, W. Jaratlerdsiri, R. J. Lyons, Haynes AM, A. A. Kulidjian, Kalsbeek AMF, D. C. Petersen, Stricker PD, C. A. M. Jamieson, P. I. Croucher, C. M. Hovens, A. M. Joshua and V. M. Hayes (2020). “The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. Cancers (Basel) 12(5). https://doi.org/10.3390/cancers12051178.

Sunny Z. Wu, Daniel L. Roden, Ghamdan Al-Eryani, Nenad Bartonicek, Kate Harvey, Aurélie S. Cazet, Chia-Ling Chan, Simon Junankar, Mun N. Hui, Ewan A. Millar, Julia Beretov, Lisa Horvath, Anthony M. Joshua, Stricker P, James S. Wilmott, Camelia Quek, Georgina V. Long, Richard A. Scolyer, Bertrand Z. Yeung, Davendra Segara, Cindy Mak, Sanjay Warrier, Joseph E. Powell, Sandra O’Toole, Elgene Lim and Alexander Swarbrick. Cryopreservation of human cancers conserves tumour heterogeneity for single- cell multi-omics analysis: Wu et al. Genome Medicine (2021) 13:81 https://doi.org/10.1186/s13073-021-00885-z

Hui-Ming Lin, Nicole Yeung, Blossom Mak, Kevin Huynh, Thomas Meikle, Natalie Mellett, Edmond Kwan, Heidi Fettke, Ben Tran, Ian Davis, Kate Mahon, Alison Zhang, Martin R. Stockler, Karen Briscoe, Gavin Marx, Megan Crumbaker, Stricker P, Pan Du, Jianjun Yu, Shidong Jia, Anthony M. Joshua, Arun Azad, Lisa M. Butler, Peter J. Meikle, Lisa G. Horvath. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedcine, 2021. Volume 72, 103625. https://doi.org/10.1016/j.ebiom.2021.103625

Michèle Orain , Valérie Picard , Hélène Hovington , Alain Bergeron , Louis Lacombe , Yves Fradet , Bernard Têtu , Weerachi Jaratlerdsiri , Eva Chan , Vanessa Haynes , Robert Lesurf , Yu-Jia Shiah , Dr Lawrence E Heisler , Shadrielle Melijah Espiritu , Vincent Huang , Christopher Lalansingh , Richard Jovelin , Vinayak Bhandari , Dorota Sendorek , Stephenie Prokopec , Michael Fraser , Adrien Foucal , Veronica Sabelnykova , Dr Jüri Reimand , Professor Stricker P , Andrew Ryan , Dr Theo van der Kwast , John D. McPherson , Takafumi Yamaguchi, Julie Livingstone , Natalie S Fox , Adriana Salcedo , Dr Kathleen E Houlahan , Lydia Liu , Professor Robert G Bristow , Natalie Kurganovs , Dr Chol-Hee Jung , Peter Georgeson , Ken Chow , Dr Michael Clarkson , Anne Nguyen , Ryan Stuchbery , Dr Marek Cmero , Patrick McCoy , Andrew Lonie , Justin Peters , Matthew Wakefield , Daniel Park , Michael Kerger , Anthony Costello , Dr Bernard Pope , Niall M Corcoran , Christopher M Hovens , Ms Helen Zhu , Professor Riana Bornman , Jocelyn Sietsma Penington , Stefano Mangiola, Lachlan Mcintosh , Professor Anthony T Papenfuss. Molecular and Evolutionary Origins of Prostate Cancer Grade. Nature NATCANCER-AN08058. 2022 11 Oct. https://mts-natcancer.nature.com/cgi-bin/main.plex?el=A6DB3DYT3A6BNZg7F4A9ftdqAS4qLnCYlFi706OfFBbkgZ

Gong T, Jaratlerdsiri W, Jiang J, Willet C, Chew T, Patrick SM, Lyons RJ, Haynes AM, Pasqualim G, Brum IS, Stricker PD, Mutambirwa SBA, Sadsad R, Papenfuss AT, Bornman RMS, Chan EKF, Hayes VM. Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers. Genome Med. 2022 Aug 31;14(1):100. https://doi.org/10.1186/s13073-022-01096-w PMID: 36045381; PMCID: PMC9434886

Craddock J, Jiang J, Patrick SM, Mutambirwa SBA, Stricker PD, Bornman MSR, Jaratlerdsiri W, Hayes VM. Alterations in the Epigenetic Machinery Associated with Prostate Cancer Health Disparities. Cancers (Basel). 2023 Jul 1;15(13):3462. https://doi.org/10.3390/cancers15133462 . PMID: 37444571; PMCID: PMC10341375.

Peters, T. J, Meyer, B, Ryan, L, Achinger-Kawecka, J, Song, J, Campbell, E. M, Qu, W, Nair, S, Loi-Luu, P, Stricker, P, Lim, E, Stirzaker, C, Clark, S. J, & Pidsley, R. (2024). Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling. BMC genomics, 25(1), 251. https://doi.org/10.1186/s12864-024-10027-5

Other

Stricker, P. D, A. B. F. Grant, B. M. Hosken, and J. S. Taylor. 1987. ‘Topical Mitomycin C Therapy for Carcinoma of the Bladder. The Journal of Urology, 138: 1164-66. https://doi.org/10.1016/S0022-5347(17)43537-3

Stricker, P.D, and A. B. F. Grant. 1988. ‘Relative Value of Antibiotics and Catheter Care in the Prevention of Urinary Tract Infection after Transurethral Prostatic Resection. British Journal of Urology, 61:494-97. https://doi.org/10.1111/j.1464-410X.1988.tb05087.x

Stricker, P. D, A. B. F. Grant, B. M. Hosken, and J. S. Taylor. 1990. ‘Topical Mitomycin C Therapy for Carcinoma in Situ of the Bladder: A Followup. The Journal of Urology, 143: 34-35. https://doi.org/10.1016/S0022-5347(17)39855-5

Stricker, P. D. 1991. ‘The Investigation of Male Sexual Dysfunction (Review). Medical Journal of Australia.

Pryor, K, J. Goddard, D. Goldstein, Stricker P, P. Russell, D. Golovsky, and R. Penny. 1995. ‘Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer, 71: 801-7.

Pryor, K, Stricker P, P. Russell, D. Golovsky, and R. Penny. 1995. ‘Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother, 41: 309-16.

Stricker, P. 1995. ‘Advances in the treatment of superficial bladder cancer: Optimising BCG Immunotherapy Case Discussions. European Urology: Supp, 32-33.

Millard, R. J, Stricker PD, and W. Lynch. 1996. ‘Risks of self-injection therapy for impotence. The Medical Journal of Australia, 165: 117-18.

Stricker, P. 1996. ‘Prostate Cancer: Don’t be too casual. The Medical Journal of Australia, 164: 319-20.

Stricker, P, K. Pryor, T. Nicholson, D. Goldstein, D. Golovsky, R. Ferguson, P. Nash, S. Ehsman, J. Rumma, G. Mammen, and R. Penny. 1996. ‘Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology, 48: 957-61; discussion 61-2.

Frydenberg, M, Stricker PD, and K. W. Kaye. 1997. ‘Prostate cancer diagnosis and management. The Lancet, 349: 1681-87. https://doi.org/10.1016/S0140-6736(96)07393-X

Frydenberg, M, G. Duchesne, and Stricker PD. 1998. ‘Management of localised prostate cancer: state of the art. Med J Aust,169: 11- 2.

Russell, P. J, S. Bennett, and Stricker P. 1998. ‘Growth factor involvement in progression of prostate cancer. Clin Chem, 44: 705-23.

Kooner, R, and Stricker P. 2000. Lower urinary tract symptoms in the male. Benign prostatic hyperplasia. MedicineToday: 20-33.

Stricker, P. 2001. Prostate Cancer Part 1. Issues in Screening and Diagnosis. MedicineToday: 20-31.

Stricker, P. 2001. Prostate Cancer Part 2. – Options in Treatment. MedicineToday, 2: 30-38.

Cagiannos, I, P. Karakiewicz, Eastham JA, M. Ohori, F. Rabbani, C. Gerigk, V. Reuter, M. Graefen, P. G. Hammerer, A. Erbersdobler, H. Huland, Kupelian P, Klein E, D. I. Quinn, S. M. Henshall, J. J. Grygiel, Sutherland RL, Stricker PD, C. G. Morash, Scardino PT, and M. W. Kattan. 2003. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol, 170:1798-803. https://doi.org/10.1097/01.ju.0000091805.98960.13

Rasiah, K. K, Stricker PD, Haynes AM, Delprado W, J. Turner J, D. Golovsky, Brenner PC,, R. Kooner, G. F. O’Neill, J. J. Grygiel, Sutherland RL, and S. M. Henshall. 2003. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer, 98: 2560-5. https://doi.org/10.1002/cncr.11850

Adshead, J, and Stricker P. 2004. Localised Prostate Cancer – Questions Patients Ask. MedicineToday, 5: 18-32.

Haxhimolla, H, S.P. David, K. K. Rasiah, Haynes AM, K Luo, D. Golovsky, and Stricker P. 2004. Solitary positive apical margin a treatment dilema. ANZ Journal of Surgery, 74: A1-A8.

Hoch, M, K. K. Rasiah, H Haxhimolla, Haynes AM, and Stricker P. 2004. Determining predictors of insignificant cancer in Gleason sum 6 prostate cancer. ANZ Journal of Surgery, 74.

Rasiah, K. K, S. M. Henshall, J. G. Kench, L. G. Horvath, D. Golovsky, Brenner PC,, R Kooner, G. O’Neill, J. Turner J, Delprado W, C. S. Lee, and P.D. Stricker. 2004. Identification of novel markers of prognosis in high grade intraepithelial neoplasia and early prostate cancer. ANZ Journal of Surgery, 74: A1-A8.

Finney, G, Haynes AM, P. Cross, P. Brenner, A. Boyn, and Stricker P. 2005. Cross-sectional analysis of sexual function after prostate brachytherapy. Urology, 66: 377-81. https://doi.org/10.1016/j.urology.2005.03.045

Karakiewicz PI, Eastham JA, M. Graefen, Cagiannos I, Stricker PD, Klein E, T. Cangiano, F. H. Schroder, Scardino PT, and M. W. Kattan. 2005. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology, 66: 1245-50. https://doi.org/10.1016/j.urology.2005.06.108

Macek P, Patel D, and Stricker P. 2005. Assessing and managing benign prostatic hyperplasia. MedicineToday, 6: 12-22.

Chabert C, Maianski Z, and Stricker P. 2007. Saw palmetto and lower urinary tract symptoms in men. MedicineToday, 8: 71-72.

Chabert C, and Stricker P. 2009. Treatment for Localised Prostate Cancer. MedicineToday, 10: 63-66.

Smith, David P, Madeleine T King, Sam Egger, Martin P Berry, Phillip D Stricker, Paul Cozzi, Jeanette Ward, Dianne L O’Connell, and Bruce K Armstrong. 2009. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ, 339. https://doi.org/10.1136/bmj.b4817

Stricker, P. 2009. A Practical Guide on PSA Testing. MedicineToday, 10.

Yuen, C, and Stricker P. 2011. Advances in the management of benign prostatic hyperplasia. MedicineToday, 12.

Stricker PD, Frydenberg M, Kneebone A, and Chopra S..2012. Informed prostate cancer risk‐adjusted testing: a new paradigm. BJU International, 110: 30-34. https://doi.org/10.1111/j.1464-410X.2012.11621.x

King, M. T, Viney R, D. P. Smith, I. Hossain, D. Street, E. Savage, S. Fowler, Berry MP, Stockler M, Cozzi P, Stricker P, J. Ward, and B. K. Armstrong. 2012. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer, 106: 638-45. https://doi.org/10.1038/bjc.2011.552

Smith, D, D O’Connell, A Bang, King MT, Berry MP, Stricker P, Cozzi P, and B. K. Armstrong. 2012. Survival in men diagnosed with prostate cancer: 8 to 10 year outcomes from the NSW Prostate Cancer Care and Outcomes Study. Abstract for Sydney Cancer Conference.

Yuen, C, T Hoassack, Haynes AM, R. DeBenito, J Mathews, Fogarty G, R. S. Jagavkar, P. Brenner, and Stricker P. 2012. Impact of percentage of positive biopsy cores on biochemical outcome in patients treated with low-dose rate (Iodine-125) brachytherapy for prostate cancer. The Open Prostate Cancer Journal, 5: 15-19.

Symons JL, Huo A, Yuen CL, Haynes AM, J. Matthews, Sutherland RL, P. Brenner, and Stricker PD. 2013. Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int, 112: 585-93. https://doi.org/10.1111/j.1464-410X.2012.11657.x

Thanigasalam, R, H. Baumert, Stricker P, P. Brenner, S. Egger, S. Chopra, J. Symons, Savdie R, A. Haynes, Bohm M, A. Elhajj, D. Smith, R. Sutherland, and K. Rasiah. 2013. Évaluation de la qualité de vie suite aux traitements actuels du cancer de prostate localisé. Progrès en Urologie, 23: 1100. https://doi.org/10.1016/j.purol.2013.08.187

Tran, M, and Stricker P. 2014. An Update on the medical management of benign prostatic hypertrophy. MedicineToday, 15: 72-76.

Gupta, R, R. O’Connell, Haynes AM, Stricker PD, Barrett W J. Turner J, Delprado W, L. G. Horvath, and J. G. Kench. 2015. Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?. BJU Int, 116: 343-50. https://doi.org/10.1111/bju.12911

Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, and C. C. Nelson. 2015. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int, 115 Suppl 5: 3-13. https://doi.org/10.1111/bju.12964

Ting F, van Leeuwen PJ, Delprado W, Haynes AM, P. Brenner, and Stricker PD. 2015. Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment. Prostate, 75: 1768-73. https://doi.org/10.1002/pros.23062

Tran, M, and Stricker P. 2015. An update on the medical management of prostate cancer. MedicineToday, 16: 42-48.

Penzias, G, A. Janowczyk, A. Singanamalli, MRusu M, Shih N Feldman M, Stricker PD, Delprado W, S. Tiwari, M. Böhm, A.M. Haynes, L. Ponsky, S.Viswanath, and A. Madabhushi. 2016. AutoStitcher: An Automated Program for Efficient and Robust Reconstruction of Digitized Whole Histological Sections from Tissue Fragments. Scientific Reports, 6: 29906. https://doi.org/10.1038/srep29906

van Leeuwen, P. J, Siriwardana A, M. Roobol, Ting F, D. Nieboer, Thompson J, W.Delprado, A.M. Haynes, P. Brenner, and Stricker P. 2016. Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies. Prostate Cancer, 2016: 7. https://doi.org/10.1155/2016/7105678

Siriwardana, A, Thompson J, and Stricker P. 2017. Personalising prostate cancer care. Part 1: Advances in diagnosis. MedicineToday, 18: 29-32.

Siriwardana, A, Thompson J, and Stricker P. 2017. Personalising prostate cancer care. Part 2: Current treatment options. MedicineToday, 18: 28-33.

Symons, J, and Stricker P. 2017. “Transperineal Prostate Biopsy. In Hinman’s Atlas of Urologic Surgery. Elsevier.

Van den Bos W, and Stricker P. 2017. Editorial Comment. The Journal of Urology, 197: 653-54. https://doi.org/10.1016/j.juro.2016.09.137

Gielchinsky, I, Chang J, Cusick T, Delprado W, Nguyen Q, Yuen C, Savdie R, Bohm M, Haynes AM, Scheltema MJ, and Stricker PD. 2018. Prostate cancer in 432 men aged < 50 years in the prostate-specific antigen era: a new outlook. BJU Int. https://doi.org/10.1111/bju.14586

Lam TBL, MacLennan S, Willemse PM, et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. 2019;76(6):790-813 https://doi.org/10.1016/j.eururo.2019.09.020

Focal Therapy

Scheltema M.J, T. J. O’Brien, van den Bos W, D. M. de Bruin, R. V. Davalos, C. W. M. van den Geld, M. P. Laguna, R. E. Neal, 2nd, I. M. Varkarakis, A. Skolarikos, Stricker PD, T. M. de Reijke, C. B. Arena and J. de la Rosette (2019). Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences. Ther Adv Urol 11: 1756287219852305. https://doi.org/10.1177/1756287219852305

Blazevski, A, Scheltema MJ, A. Amin, Thompson JE, N. Lawrentschuk and Stricker PD (2019). Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. https://doi.org/10.1111/bju.14951

Blazevski A, Scheltema MJ, Yuen B, Cusick T, Haynes A, Stricker P. Lab to Lithotomy – A history of irreversible electroporation from laboratory technique to prostate cancer treatment The Journal of Urology. 2019 April 2254-e255 https://doi.org/10.1097/01.JU.0000555425.31060.d4

van Riel LAMJG, Geboers B, Kabaktepe E, Blazevski A, Reesink DJ, Stijns P, Stricker PD, Casanova J, Dominguez-Escrig JL, de Reijke TM, Scheltema MJ, Oddens JR. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU Int. 2022 Apr 27. https://doi.org/10.1111/bju.15759. Epub ahead of print.

Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ; Focal Therapy Society. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023 Jul 5:S0302-2838(23)02943-3. https://doi.org/10.1016/j.eururo.2023.06.013 0.1016/j.eururo.2023.06.013 . Epub ahead of print. PMID: 37419773.

Active Surveillance

Bayliss, D, J. Duff, Stricker P, and K. Walker. 2016. Decision-Making in Prostate Cancer: Active Surveillance Over Other Treatment Options. Urol Nurs, 36: 141-9.

Cooperberg MR, Zheng Y, Faino AV, et al. Tailoring intensity of Active surveillance for low-risk prostate cancer based on online August 27, 2020. http://DOI:10.1001/jamaoncol.2020.3187

Imaging

Siriwardana, A, W van den Bos, Thompson J, Shnier R, and P.D. Stricker. 2017. The role of MRI in prostate cancer: A changing paradigm. MedicineToday, 18 .

Thompson J, and Stricker P. 2017. MRI improves cost and accuracy of prostate cancer biopsy. Nature Reviews Urology, 15: 6. https://doi.org/10.1038/nrurol.2017.185

Thompson JE, and Stricker PD. 2017. Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. Lancet, 389: 767-68. https://doi.org/10.1016/s0140-6736(17)30121-6

Thompson, J. E, and Stricker PD. 2018. MRI improves active surveillance of prostate cancer however biopsy is still crucial. BJU Int, 122: E1-E2. https://doi.org/10.1111/bju.14424

Louise Emmett, James Buteau, Nathan Papa, Daniel Moon, James Thompson, Matthew Roberts, Kris Rasiah, David Pattison, John Yaxley, Paul Thomas, Anthony Hutton, Shikha Agrawal, Amer Amin, Alexandar Blazevski, Venu Chalasani, Bao Ho, Andrew Nguyen, Victor Liu, Jonathan Lee, Gemma Sheehan-Dare, Raji Kooner, Geoff Coughlin, Lyn Chan, Thomas Cusick, Benjamin Namdarian, Jada Kapoor, Omar Alghazo, Henry Woo, Nathan Lawrentschuk, Declan Murphy, Michael Hofman, Stricker P. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography To Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021.ISSN 0302-2838. https://doi.org/10.1016/j.eururo.2021.08.002

Louise M Emmett, Nathan Papa, James Buteau, Bao Ho, Victor Liu, Matthew Roberts, James Thompson, Daniel Moon, Gemma Sheehan-Dare, Omar Alghazo, Shikha Agrawal, Declan G. Murphy, Stricker P, Thomas A. Hope and Michael Hofman. The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. Journal of Nuclear Medicine March 2022, jnumed.121.263448; https://doi.org/10.2967/jnumed.121.263448

Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, Hofman M, Buteau J, Murphy DG, Emmett L, Moon D. High PSMA PET SUVmax in PI‐RADS 4 or 5 men confers a high probability of significant prostate cancer. BJU International. 2022 Apr 1. https://doi.org/10.1111/bju .15736

Doan P, Counter W, Papa N, Sheehan-Dare G, Ho B, Lee J, Liu V, Thompson JE, Agrawal S, Roberts MJ, Buteau J, Hofman MS, Moon D, Lawrentschuk N, Murphy D, Stricker PD, Emmett L. Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer. BJU Int. 2022 Nov 13. https://doi.org/10.1111/bju.15929. Epub ahead of print. PMID: 36371669. https://pubmed.ncbi.nlm.nih.gov/36371669/

Vis AN, Meijer D, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, Samaratunga H, Emmett L, van de Ven PM, Heymans MW, Nieuwenhuijzen JA, van der Poel HG, Donswijk ML, Boellaard TN, Schoots IG, Stricker P, Haynes AM, Oprea-Lager DE, Coughlin GD, van Leeuwen PJ. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 Apr 10:S2588-9311(23)00075-5. DOI: 10.1016/j.euo.2023.03.010. Epub ahead of print. PMID: 37045707.
Kelly B, Ptasznik G, Roberts MJ, Doan P, Stricker P, Thompson J, Buteau J, Chen K, Alghazo O, O’Brien JS, Hofman MS, Frydenberg M, Lawrentschuk N, Lundon D, Murphy DG, Emmett L and Moon D. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy, European Urology Open Science. 2023. https://doi.org/10.1016/j.euros.2023.05.002

Azargoshasb S, Hilda A. de Barros, Rietbergen D, Dell’Oglio P, Van Leeuwen PJ, Wagner C, Stricker P, Sergi Vidal-Sicart, Alberto Briganti, Tobias Maurer, Henk G. van der Poel, Matthias N. van Oosterom, Fijs W. B. van Leeuwen. Artificial Intelligence-Supported Video Analysis as a Means to Assess the Impact of DROP-IN Image Guidance on Robotic Surgeons: Radioguided Sentinel Lymph Node versus PSMA-Targeted Prostate Cancer Surgery. Advanced Intelligent Systems journal. 2023. https://doi.org/10.1002/aisy.202300192

Radical Prostatectomy/Robotic Surgery

Quinn, D. I, S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, Brenner PC,, J. Turner J, Delprado WJF, Finlayson, Stricker PD, J. J. Grygiel, and Sutherland RL. 2000. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res, 60: 1585-94.

Quinn, D. I, S.M. Henshall, A.M. Haynes, Brenner PC,, R. Kooner, D. Golovsky, J. Mathews, G. F. O’Neill, J. Turner J, Delprado WJF, Finlayson, Sutherland RL, J. J. Grygiel, and Stricker PD. 2001. Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models. Journal of Clinical Oncology, 19: 3692-705. https://doi.org/10.1200/jco.2001.19.16.3692